Background. Although terminal cancer is a widely used term, its meaning varies, which may lead to different attitudes toward end-of-life issues. The study was conducted to investigate differences in the understanding of terminal cancer and determine the relationship between this understanding and attitudes toward end-of-life issues. Methods. A questionnaire survey was performed between 2008 and 2009. A total of 1242 cancer patients, 1289 family caregivers, 303 oncologists from 17 hospitals, and 1006 participants from the general population responded. Results. A “6-month life expectancy” was the most common understanding of terminal cancer (45.6%), followed by “treatment refractoriness” (21.1%), “metastatic/recurrent disease” (19.4%), “survival of a few days/weeks” (11.4%), and “locally advanced disease” (2.5%). The combined proportion of “treatment refractoriness” and “6-month life expectancy” differed significantly between oncologists and the other groups combined (76.0% v. 65.9%, P = 0.0003). Multivariate analyses showed that patients and caregivers who understood terminal cancer as “survival of a few days/weeks” showed more negative attitudes toward disclosure of terminal status compared with participants who chose “treatment refractoriness” (adjusted odds ratio [aOR] 0.42, 95% confidence interval [CI] 0.22–0.79 for patients; aOR 0.34, 95% CI 0.18–0.63 for caregivers). Caregivers who understood terminal cancer as “locally advanced” or “metastatic/recurrent disease” showed a significantly lower percentage of agreement with withdrawal of futile life-sustaining treatment compared with those who chose “treatment refractoriness” (aOR 0.19, 95% CI 0.07–0.54 for locally advanced; aOR 0.39, 95% CI 0.21–0.72 for metastatic/recurrent). Conclusions. The understanding of terminal cancer varied among the 4 participant groups. It was associated with different preferences regarding end-of-life issues. Standardization of these terms is needed to better understand end-of-life care.
PeppercornJMSmithTJHelftPR. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755–60.
2.
KasperDLBraunwaldEFauciAS. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2005.
3.
EmanuelEJEmanuelLL. The promise of a good death. Lancet. 1998;351:SII21–9.
4.
SchofieldPCareyMLoveANehillCWeinS. “Would you like to talk about your future treatment options?” Discussing the transition from curative cancer treatment to palliative care. Palliat Med. 2006;20(4):397.
SmithTJTeminSAlesiER. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880–7.
10.
YunYHLeeMKKimSY. Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. J Clin Oncol. 2011;29(18):2474–80.
11.
ChristakisNAEscarceJJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med. 1996;335(3):172–8.
12.
ÅbomBKragstrupJVondelingHBakketeigLSStovringH. Defining cancer patients as being in the terminal phase: who receives a formal diagnosis, and what are the effects?J Clin Oncol. 2005;23(30):7411–6.
13.
MoritaTIchikiTTsunodaJInoueSChiharaS. A prospective study on the dying process in terminally ill cancer patients. Am J Hosp Palliat Med. 1998;15(4):217–22.
14.
OhDYKimJELeeCH. Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer. 2004;100(9):1961–6.
15.
DesharnaisSCarterREHennessyWKurentJECarterC. Lack of concordance between physician and patient: reports on end-of-life care discussions. J Palliat Med. 2007;10(3):728–40.
16.
HaidetPHamelMBDavisRB. Outcomes, preferences for resuscitation, and physician-patient communication among patients with metastatic colorectal cancer. Am J Med. 1998;105(3):222–9.
17.
TangSTLiuTWLaiMSLiuLNChenCH. Concordance of preferences for end-of-life care between terminally ill cancer patients and their family caregivers in Taiwan. J Pain Symptom Manage. 2005;30(6):510–8.
18.
YunYHHanKHParkS. Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients. CMAJ. 2011;183(10):E673–9.
19.
MoritaTTsunodaJInoueSChiharaS. Survival prediction of terminally ill cancer patients by clinical symptoms: development of a simple indicator. Jpn J Clin Oncol. 1999;29(3):156–9.
20.
FeliuJJiménez-GordoAMMaderoR. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst. 2011;103(21):1613–20.
21.
MoritaTTsunodaJInoueSChiharaS. Improved accuracy of physicians’ survival prediction for terminally ill cancer patients using the Palliative Prognostic Index. Palliat Med. 2001;15(5):419–24.
22.
LloberaJEstevaMRifaJ. Terminal cancer: duration and prediction of survival time. Eur J Cancer. 2000;36(16):2036–43.
23.
SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
24.
MokTSWuYLThongprasertS. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
25.
Van KleffensTVan LeeuwenE. Physicians’ evaluations of patients’ decisions to refuse oncological treatment. J Med Ethics. 2005;31(3):131–6.
26.
VerhoefMJRoseMWhiteMBalneavesL. Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge?Curr Oncol. 2008;15(s2):s101.
27.
MackillopWStewartWGinsburgAStewartS. Cancer patients’ perceptions of their disease and its treatment. Br J Cancer. 1988;58(3):355.
28.
PronzatoPBertelliGLosardoPLanducciM. What do advanced cancer patients know of their disease?Support Care Cancer. 1994;2(4):242–4.
29.
AdamJ. ABC of palliative care: the last 48 hours. BMJ. 1997;315(7122):1600–3.
30.
MoritaTAkechiTIkenagaM. Late referrals to specialized palliative care service in Japan. J Clin Oncol. 2005;23(12):2637.
31.
BaekYJShinDWChoiJY. Late referral to palliative care services in Korea. J Pain Symptom Manage. 2011;41(4):692–9.
32.
LaurieSAHoALFuryMGShermanEPfisterDG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–24.
33.
van KleffensTvan LeeuwenE. Physicians’ evaluations of patients’ decisions to refuse oncological treatment. J Med Ethics. 2005;31(3):131–6.
34.
YunYHKwonYCLeeMK. Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. J Clin Oncol. 2010;28(11):1950.
35.
SmediraNGEvansBHGraisLS. Withholding and withdrawal of life support from the critically ill. N Engl J Med. 1990;322(5):309–15.
36.
McCabeMSWoodWAGoldbergRM. When the family requests withholding the diagnosis: who owns the truth?J Oncol Pract. 2010;6(2):94–6.
37.
ZierLSBurackJHMiccoGChipmanAKFrankJAWhiteDB. Surrogate decision makers’ responses to physicians’ predictions of medical futility. Chest. 2009;136(1):110–7.
38.
BlackhallLJMurphySTFrankG. Ethnicity and attitudes toward patient autonomy. JAMA1995;13;274(10):820–5.
39.
BerkmanCSKoE. Preferences for disclosure of information about serious illness among older Korean American immigrants in New York City. J Palliat Med2009;12(4):351–7.
40.
LeeJKKeamBAnAR. Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. Support Care Cancer2012; 21(1):183–90.
41.
Korean Statistical Information Service. Available from: URL: http://kosis.kr
